Guidance Capital Inc. Decreases Stake in Bristol-Myers Squibb (NYSE:BMY)

Guidance Capital Inc. cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 7.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,939 shares of the biopharmaceutical company’s stock after selling 815 shares during the quarter. Guidance Capital Inc.’s holdings in Bristol-Myers Squibb were worth $539,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of BMY. Bank of Nova Scotia boosted its stake in shares of Bristol-Myers Squibb by 13.7% in the third quarter. Bank of Nova Scotia now owns 208,970 shares of the biopharmaceutical company’s stock valued at $12,129,000 after buying an additional 25,153 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 1,004.9% in the third quarter. Schonfeld Strategic Advisors LLC now owns 94,351 shares of the biopharmaceutical company’s stock valued at $5,476,000 after buying an additional 85,812 shares in the last quarter. Waverly Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 11.5% in the third quarter. Waverly Advisors LLC now owns 10,485 shares of the biopharmaceutical company’s stock valued at $609,000 after buying an additional 1,078 shares in the last quarter. United Services Automobile Association boosted its position in Bristol-Myers Squibb by 17.3% during the third quarter. United Services Automobile Association now owns 56,179 shares of the biopharmaceutical company’s stock worth $3,261,000 after purchasing an additional 8,286 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its position in Bristol-Myers Squibb by 26.2% during the third quarter. Jones Financial Companies Lllp now owns 16,112 shares of the biopharmaceutical company’s stock worth $935,000 after purchasing an additional 3,341 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BMY shares. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Barclays decreased their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, BMO Capital Markets cut their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Trading Up 0.0 %

Bristol-Myers Squibb stock traded up $0.02 during trading on Friday, hitting $41.53. The company’s stock had a trading volume of 20,542,742 shares, compared to its average volume of 15,934,426. The stock has a market capitalization of $84.19 billion, a price-to-earnings ratio of -13.40, a P/E/G ratio of 14.20 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The stock’s fifty day moving average is $42.97 and its 200 day moving average is $48.14. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.38.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 earnings per share. As a group, equities research analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.78%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.